The 2016 to 2026 Kratom Timeline

The modern American kratom market cannot be understood without the decade between the 2016 DEA scheduling fight and the 2026 federal action around 7-OH.

The decade was shaped by changing products and human use

From 2016 to 2026, the U.S. market expanded from a leaf-and-powder debate into concentrated extracts, MIT tablets, enriched 7-OH, and synthetic derivatives. These products differ in psychoactive compound identity and exposure, while dependence, poison-center reports, and uncertain product composition have driven regulatory attention.

The central change was not that kratom suddenly became psychoactive. It was that concentrated and semi-synthetic products could deliver very different alkaloid exposure from ordinary leaf while using familiar kratom language. The timeline below is easier to understand when product evolution and human effects remain connected.

2016: the scheduling fight that shaped the industry

In 2016, DEA announced its intent to temporarily place mitragynine and 7-hydroxymitragynine into Schedule I. The response was immediate. Consumers, vendors, researchers, advocacy groups, and members of Congress pushed back. DEA later withdrew the notice and opened the issue to public comment. That reversal became one of the defining moments in American kratom history.

The 2016 fight taught the kratom community that public comments, consumer stories, congressional attention, and organized advocacy could matter. It also created a lasting reflex: many people in the category learned to treat every federal kratom mention as a potential emergency.

That reflex is understandable, but it can also make the industry miss important distinctions. The 2026 7-OH action is not simply a replay of 2016. It is narrower, more focused on synthetic or elevated 7-OH, and supported by parts of the mainstream kratom industry that want to protect normal kratom products.

2017 to 2024: a state-by-state marketplace

After 2016, the U.S. market grew through online stores, smoke shops, supplement retailers, and specialty vendors. States and cities moved in different directions. Some restricted kratom. Some considered regulation. Some adopted consumer-protection-style approaches. Others left the category in a gray space where vendors had to monitor local rules carefully.

During this period, older kratom education focused heavily on strain names, powders, capsules, and general definitions. That content still has value, but it does not answer the newer questions customers ask now: What is MIT? What is 7-OH? How do I read a COA? Why are laws treating different product types differently?

The market also changed visually. Better product photography, stronger packaging, bulk offerings, extract-style products, and convenience-store formats all reshaped what kratom looked like to the public.

2025: FDA turns the spotlight toward 7-OH

In 2025, FDA publicly focused on 7-OH products and emphasized that its concern was not natural kratom leaf products as such. That distinction was important. It signaled a more focused federal argument: separate ordinary kratom from products built around isolated, synthetic, or elevated 7-OH.

By then, many 7-OH products had developed their own retail culture: packets, shots, tablets, strips, and loud packaging. That made the category easier for regulators and reporters to see. It also made it easier for responsible kratom brands to argue that synthetic 7-OH should not be allowed to define the entire plant market.

2026: the federal line becomes public

In July 2026, DEA published separate notices concerning a proposed threshold for 7-OH and three related substances. On August 26, DEA's temporary order placed mitragynine pseudoindoxyl, MGM-15, and MGM-16 in Schedule I through August 26, 2028 unless the order is extended or made permanent.

The proposed threshold for 7-OH remained a separate process. HHS extended comments on that threshold through September 10, 2026. That distinction changed the conversation from a single “kratom ban” headline into product-specific questions about compound identity, concentration, processing, and jurisdiction.

Kratom Paradise keeps botanical leaf, MIT products, and synthetic or enriched 7-OH in separate catalog and information lanes. Those categories should not be collapsed into one legal or pharmacological conclusion.

2016 DEA withdrawal notice. DEA August 26, 2026 temporary order. HHS 7-OH threshold-comment extension.

What changed across the decade

The 2016 scheduling fight, the state-by-state period that followed, the rise of MIT labeling, the growth of convenience-store formats, and the 2025-2026 focus on 7-OH form one connected history.

In 2016, the central federal question focused broadly on mitragynine and 7-hydroxymitragynine. By 2026, policy discussions placed greater emphasis on product type, concentration, synthesis, labeling, and the boundary between botanical leaf and 7-OH-centered products.

The market changed alongside the policy debate. Powder and capsule catalogs were joined by MIT labels, extract formats, new packaging styles, laboratory documentation, and larger bulk options.

Understanding that history makes today's labels and legal distinctions easier to read. Botanical kratom, clearly labeled MIT products, and synthetic or elevated 7-OH now occupy visibly different parts of the public conversation.